Calculating Anti-VEGF Treatment Costs

Information on which anti-VEGF medicine (ranibizumab, bevacizumab or aflibercept) was administered to each patient was obtained from the EPR, and the unit prices were obtained from the hospital pharmacy. The medicine costs for all patients were summed and divided by the number of injections to find the average medicine cost per injection. The equipment costs included the aggregated volume of disposable equipment at purchase price and the cost of cleaning reusable equipment, divided by the number of injections (Table 4).

Free full text: Click here

Bolme S., Austeng D., Morken T.S., Follestad T, & Halsteinli V. (2023). Cost consequences of task-shifting intravitreal injections from physicians to nurses in a tertiary hospital in Norway. BMC Health Services Research, 23, 229.

Publication 2023

Aflibercept Bevacizumab Medicine Patients Ranibizumab Vegf

Corresponding Organization :

Other organizations : St Olav's University Hospital, Norwegian University of Science and Technology

Top 5 similar protocols

Variable analysis

independent variables

Type of anti-VEGF medicine (ranibizumab, bevacizumab, or aflibercept)

dependent variables

Average medicine cost per injection
Equipment costs per injection

control variables

None explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!